214 related articles for article (PubMed ID: 27225838)
21. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
[TBL] [Abstract][Full Text] [Related]
22. Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising
Qian W; Li X; Liu Q; Lu J; Wang T; Zhang Q
Front Cell Infect Microbiol; 2022; 12():884793. PubMed ID: 35669114
[TBL] [Abstract][Full Text] [Related]
23. Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro.
Pereira de Sá N; Lino CI; Fonseca NC; Borelli BM; Ramos JP; Souza-Fagundes EM; Rosa CA; Santos DA; Barbosa de Oliveira R; Johann S
Eur J Med Chem; 2015 Sep; 102():233-42. PubMed ID: 26276437
[TBL] [Abstract][Full Text] [Related]
24. Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.
Sá NP; Lima CM; Lino CI; Barbeira PJS; Baltazar LM; Santos DA; Oliveira RB; Mylonakis E; Fuchs BB; Johann S
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533240
[TBL] [Abstract][Full Text] [Related]
25. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
27. Antifungal potential of punicalagin against Cryptococcus neoformans species complex.
Silva TC; Zara ALSA; Sá FADS; Bara MTF; Ávila RI; Costa CR; Valadares MC; Santos ASD; Freitas VAQ; Silva MDRR
Rev Inst Med Trop Sao Paulo; 2018 Oct; 60():e60. PubMed ID: 30365643
[TBL] [Abstract][Full Text] [Related]
28. A flow cytometry method for testing the susceptibility of Cryptococcus spp. to amphotericin B.
Benaducci T; Matsumoto MT; Sardi JC; Fusco-Almeida AM; Mendes-Giannini MJ
Rev Iberoam Micol; 2015; 32(3):159-63. PubMed ID: 25639695
[TBL] [Abstract][Full Text] [Related]
29. Antifungal efficacy of ten selected South African plant species against Cryptococcus neoformans.
Mokoka TA; McGaw LJ; Eloff JN
Pharm Biol; 2010 Apr; 48(4):397-404. PubMed ID: 20645717
[TBL] [Abstract][Full Text] [Related]
30. Antifungal activity of plumericin and isoplumericin.
Singh D; Sharma U; Kumar P; Gupta YK; Dobhal MP; Singh S
Nat Prod Commun; 2011 Nov; 6(11):1567-8. PubMed ID: 22224260
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility testing of Cryptococcus neoformans using the urea broth microdilution method.
Nakamura Y; Kano R; Watanabe S; Takahashi H; Hasegawa A
Mycoses; 1998; 41(1-2):41-4. PubMed ID: 9610132
[TBL] [Abstract][Full Text] [Related]
32. Inibitory effects of linalool on fungal pathogenicity of clinical isolates of Microsporum canis and Microsporum gypseum.
Silva KVS; Lima MIO; Cardoso GN; Santos AS; Silva GS; Pereira FO
Mycoses; 2017 Jun; 60(6):387-393. PubMed ID: 28198097
[TBL] [Abstract][Full Text] [Related]
33. 3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans.
Dyląg M; Lis P; Niedźwiecka K; Ko YH; Pedersen PL; Goffeau A; Ułaszewski S
Biochem Biophys Res Commun; 2013 May; 434(2):322-7. PubMed ID: 23541578
[TBL] [Abstract][Full Text] [Related]
34. Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
Ko HT; Hsu LH; Yang SY; Chen YL
Med Mycol; 2020 Jun; 58(4):493-504. PubMed ID: 31297540
[TBL] [Abstract][Full Text] [Related]
35. A microautomated dilution method for susceptibility testing with antifungal drugs.
Polonelli L; Morace G
Mycopathologia; 1984 Apr; 86(1):21-8. PubMed ID: 6377080
[TBL] [Abstract][Full Text] [Related]
36. Antifungal activity of promethazine and chlorpromazine against planktonic cells and biofilms of Cryptococcus neoformans/Cryptococcus gattii complex species.
Brilhante RSN; Gotay WJP; Pereira VS; de Oliveira JS; Pereira-Neto WA; Castelo-Branco DSCM; Cordeiro RA; Sidrim JJC; Rocha MFG
Med Mycol; 2020 Oct; 58(7):906-912. PubMed ID: 32016364
[TBL] [Abstract][Full Text] [Related]
37. Effects of microplusin, a copper-chelating antimicrobial peptide, against Cryptococcus neoformans.
Silva FD; Rossi DC; Martinez LR; Frases S; Fonseca FL; Campos CB; Rodrigues ML; Nosanchuk JD; Daffre S
FEMS Microbiol Lett; 2011 Nov; 324(1):64-72. PubMed ID: 22092765
[TBL] [Abstract][Full Text] [Related]
38. Antifungal Activity, Mode of Action, Docking Prediction and Anti-biofilm Effects of (+)-β-pinene Enantiomers against Candida spp.
de Macêdo Andrade AC; Rosalen PL; Freires IA; Scotti L; Scotti MT; Aquino SG; de Castro RD
Curr Top Med Chem; 2018; 18(29):2481-2490. PubMed ID: 30430938
[TBL] [Abstract][Full Text] [Related]
39. [Efficiency of ethanol of Thonningia sanguinea against Cryptococcus neoformans].
Ouattara B; Kra AM; Coulibaly A; Guede-Guina F
Sante; 2007; 17(4):219-22. PubMed ID: 18299265
[TBL] [Abstract][Full Text] [Related]
40. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
